A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma: a final report
Background The use of chemotherapy to manage newly diagnosed low grade glioma (LGG) was first introduced in the 1980s. One randomised trial has studied two- versus four-drug regimens with a duration of 12 months of treatment after resection. Methods Within the European comprehensive treatme...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Elsevier
2017
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/44511/ |
| _version_ | 1848796932707713024 |
|---|---|
| author | Gnekow, Astrid K. Walker, David A. Kandels, Daniela Picton, Susan Perilongo, Giorgio Grill, Jacques Stokland, Tore Sandstrom, Per Eric Warmuth-Metz, Monika Pietsch, Torsten Giangaspero, Felice Schmidt, René Faldum, Andreas Kilmartin, Denise De Paoli, Angela De Salvo, Gian Luca |
| author_facet | Gnekow, Astrid K. Walker, David A. Kandels, Daniela Picton, Susan Perilongo, Giorgio Grill, Jacques Stokland, Tore Sandstrom, Per Eric Warmuth-Metz, Monika Pietsch, Torsten Giangaspero, Felice Schmidt, René Faldum, Andreas Kilmartin, Denise De Paoli, Angela De Salvo, Gian Luca |
| author_sort | Gnekow, Astrid K. |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Background
The use of chemotherapy to manage newly diagnosed low grade glioma (LGG) was first introduced in the 1980s. One randomised trial has studied two- versus four-drug regimens with a duration of 12 months of treatment after resection.
Methods
Within the European comprehensive treatment strategy for childhood LGG, the International Society of Paediatric Oncology–Low Grade Glioma (SIOP LGG) Committee launched a randomised trial involving 118 institutions and 11 countries to investigate the addition of etoposide (100 mg/m2, days 1, 2 & 3) to a four-course induction of vincristine (1.5 mg/m2 × 10 wkly) and carboplatin (550 mg/m2 q 3 weekly) as part of 18-month continuing treatment programme. Patients were recruited after imaging diagnosis, resection or biopsy with progressive disease/symptoms. Some 497 newly diagnosed patients (M/F 231/266; median age 4.26 years (interquartile range (IQR) 2.02–7.06)) were randomised to receive vincristine carboplatin (VC) (n = 249) or VC plus etoposide (VCE) during induction (n = 248), stratified by age and tumour site.
Findings
No differences between the two arms were found in term of survival and radiological response. Response and non-progression rates at 24 weeks for VC and VCE, were 46% versus 41%, and 93% versus 91% respectively; 5-year Progression-Free Survival (PFS) and Overall Survival (OS) were 46% (StDev 3.5) versus 45% (StDev 3.5) and 89% (StDev 2.1) versus 89% (StDev 2.1) respectively. Age and diencephalic syndrome are adverse clinical risk factors for PFS and OS. 5-year OS for patients in early progression at week 24 were 46% (StDev 13.8) and 49% (StDev 16.5) in the two arms, respectively.
Interpretation
The addition of etoposide to VC did not improve PFS or OS. High non-progression rates at 24 weeks justify retaining VC as standard first-line therapy. Infants with diencephalic syndrome and early progression need new treatments to be tested. Future trials should use neurological/visual and toxicity outcomes and be designed to discriminate between the impact on disease outcomes of ‘duration of therapy’ and ‘age at stopping therapy’. |
| first_indexed | 2025-11-14T19:55:50Z |
| format | Article |
| id | nottingham-44511 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T19:55:50Z |
| publishDate | 2017 |
| publisher | Elsevier |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-445112020-05-04T19:04:01Z https://eprints.nottingham.ac.uk/44511/ A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma: a final report Gnekow, Astrid K. Walker, David A. Kandels, Daniela Picton, Susan Perilongo, Giorgio Grill, Jacques Stokland, Tore Sandstrom, Per Eric Warmuth-Metz, Monika Pietsch, Torsten Giangaspero, Felice Schmidt, René Faldum, Andreas Kilmartin, Denise De Paoli, Angela De Salvo, Gian Luca Background The use of chemotherapy to manage newly diagnosed low grade glioma (LGG) was first introduced in the 1980s. One randomised trial has studied two- versus four-drug regimens with a duration of 12 months of treatment after resection. Methods Within the European comprehensive treatment strategy for childhood LGG, the International Society of Paediatric Oncology–Low Grade Glioma (SIOP LGG) Committee launched a randomised trial involving 118 institutions and 11 countries to investigate the addition of etoposide (100 mg/m2, days 1, 2 & 3) to a four-course induction of vincristine (1.5 mg/m2 × 10 wkly) and carboplatin (550 mg/m2 q 3 weekly) as part of 18-month continuing treatment programme. Patients were recruited after imaging diagnosis, resection or biopsy with progressive disease/symptoms. Some 497 newly diagnosed patients (M/F 231/266; median age 4.26 years (interquartile range (IQR) 2.02–7.06)) were randomised to receive vincristine carboplatin (VC) (n = 249) or VC plus etoposide (VCE) during induction (n = 248), stratified by age and tumour site. Findings No differences between the two arms were found in term of survival and radiological response. Response and non-progression rates at 24 weeks for VC and VCE, were 46% versus 41%, and 93% versus 91% respectively; 5-year Progression-Free Survival (PFS) and Overall Survival (OS) were 46% (StDev 3.5) versus 45% (StDev 3.5) and 89% (StDev 2.1) versus 89% (StDev 2.1) respectively. Age and diencephalic syndrome are adverse clinical risk factors for PFS and OS. 5-year OS for patients in early progression at week 24 were 46% (StDev 13.8) and 49% (StDev 16.5) in the two arms, respectively. Interpretation The addition of etoposide to VC did not improve PFS or OS. High non-progression rates at 24 weeks justify retaining VC as standard first-line therapy. Infants with diencephalic syndrome and early progression need new treatments to be tested. Future trials should use neurological/visual and toxicity outcomes and be designed to discriminate between the impact on disease outcomes of ‘duration of therapy’ and ‘age at stopping therapy’. Elsevier 2017-08-31 Article PeerReviewed Gnekow, Astrid K., Walker, David A., Kandels, Daniela, Picton, Susan, Perilongo, Giorgio, Grill, Jacques, Stokland, Tore, Sandstrom, Per Eric, Warmuth-Metz, Monika, Pietsch, Torsten, Giangaspero, Felice, Schmidt, René, Faldum, Andreas, Kilmartin, Denise, De Paoli, Angela and De Salvo, Gian Luca (2017) A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma: a final report. European Journal of Cancer, 81 . pp. 206-225. ISSN 0959-8049 Low grade glioma; Childhood; Chemotherapy; Randomised trial https://doi.org/10.1016/j.ejca.2017.04.019 doi:10.1016/j.ejca.2017.04.019 doi:10.1016/j.ejca.2017.04.019 |
| spellingShingle | Low grade glioma; Childhood; Chemotherapy; Randomised trial Gnekow, Astrid K. Walker, David A. Kandels, Daniela Picton, Susan Perilongo, Giorgio Grill, Jacques Stokland, Tore Sandstrom, Per Eric Warmuth-Metz, Monika Pietsch, Torsten Giangaspero, Felice Schmidt, René Faldum, Andreas Kilmartin, Denise De Paoli, Angela De Salvo, Gian Luca A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma: a final report |
| title | A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma: a final report |
| title_full | A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma: a final report |
| title_fullStr | A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma: a final report |
| title_full_unstemmed | A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma: a final report |
| title_short | A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma: a final report |
| title_sort | european randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma: a final report |
| topic | Low grade glioma; Childhood; Chemotherapy; Randomised trial |
| url | https://eprints.nottingham.ac.uk/44511/ https://eprints.nottingham.ac.uk/44511/ https://eprints.nottingham.ac.uk/44511/ |